Navigation Links
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Date:9/11/2007

Fast Track-Designated Study Approved Under FDA Special Protocol Assessment

Process Could Expand Indication to Indolent NHL

SEATTLE, Sept. 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced the launch of its phase III clinical trial, known as PIX303, of pixantrone for patients with indolent non-Hodgkin's lymphoma (NHL) who have relapsed following first-line therapy. The Company has a Special Protocol Assessment (SPA) in place with the U.S. Food and Drug Administration (FDA) for PIX303. The trial will examine progression-free survival (PFS), which is the rate at which a patient's lymphoma recurs or progresses, following treatment with pixantrone, fludarabine, and rituximab (FP-R) compared to treatment with fludarabine and rituximab (F-R), a commonly used second-line regimen in relapsed indolent NHL. The randomized, multi-center, multi-national trial is expected to enroll 300 patients, to be completed over a 12 to 16 month period. Dependant on the rate of progression, an interim analysis is targeted in 2009 and, if successful, could serve as a potential supplemental indication for pixantrone. Pixantrone has received fast track designation from the FDA for this indication.

"We have previously shown in a randomized controlled trial that the addition of pixantrone to rituximab significantly increased median time to progression over rituximab alone (13.0 months versus 8.1 months for rituximab alone; p<0.001) in relapsed indolent NHL patients," said James A. Bianco, M.D., President and CEO of CTI. "That data, coupled with the marked increase in PFS when pixantrone was added to a fludarabine-based regimen, provides a strong rationale for proceeding with thi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015   InspireMD, Inc.  ("InspireMD" or the ... systems ("EPS"), today announced that it has entered into ... million shares of common stock and warrants to purchase ... in a public offering.  The common stock will be ... share, and each purchaser will receive a warrant to ...
(Date:3/4/2015)... Israël, 4 mars 2015 /PRNewswire/ ... (« RedHill » ou la « Société »), une ... sur les spécialités pharmaceutiques administrés ... stade clinique avancé pour les ... notamment les cancers gastro-intestinaux, a ...
(Date:3/4/2015)... -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ) announced today ... at the Ritz-Carlton at Laguna Niguel, California ... Arthur S. Przybyl , President and CEO, will give the ... ANI,s website at www.anipharmaceuticals.com . Mr. Przybyl,s presentation will ... available through the link through June 7, 2015. ...
Breaking Medicine Technology:InspireMD Announces Public Offering for Approximately $13.5 Million 2InspireMD Announces Public Offering for Approximately $13.5 Million 3InspireMD Announces Public Offering for Approximately $13.5 Million 4RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 2RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 3RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 4RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 5ANI Pharmaceuticals To Present At 27th Annual ROTH Conference 2
... YORK, Jan. 12, 2011 NeoStem, Inc. (NYSE Amex: ... company with operations in the U.S. and China, today announced ... present on Wednesday, January 12, 2011 at the OneMedForum 2011 ... at 11:00 AM PST. Both events will be held in ...
... InstaCare Corp. (OTC Bulletin Board:  ISCR) a ... testing products for the chronically ill, a leading ... and a leading developer of revolutionary cell phone ... company,s Board of Directors has received the initial ...
Cached Medicine Technology:NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011 2NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011 3InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA 2
(Date:3/4/2015)... Nitrosigine®, a patented complex of bonded arginine silicate ... is hosting the Nitrosigine Pump Challenge at the America’s ... The Arnold Sports Festival in Columbus, Ohio. The event ... 2015. , Nitrosigine is a patented ingredient of ... status; now affirmed as GRAS.^ It has been clinically ...
(Date:3/4/2015)... The report “Vasculitis – Pipeline Review, H1 ... Vasculitis. Vasculitis is a disease that features tenderness of ... is not known. Vasculitis can affect any body system ... can include fever, weight loss, tiredness, aches, pains, night ... limb. Vasculitis is treatable, but it is not curable. ...
(Date:3/4/2015)... The week of March 2nd - 8th ... Awareness Day being recognized on March 13th, the aim ... risks associated with sleep related illnesses, costing the United ... of America have turned to social media with an ... virally inspire conversation regarding the disease. , The ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... a worrisome public health issue worldwide. The rising prevalence ... economic and social burden in both developed and developing ... is projected to rise to 1.5 billion, equating to ... of these patients are forecast to come from the ...
(Date:3/4/2015)... Bird B Gone, the leader in ... now offers its popular plastic (polycarbonate) bird spike in ... bird deterrent is ready-to-use and comes in ... décor of the building or structure onto which it ... clear, light grey, brown, black and tan—make the spikes ...
Breaking Medicine News(10 mins):Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 2Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 3Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 4Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 2Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 3Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 4Health News:Plastic Bird Spikes Now Come in 7 Colors to Blend in With Their Surroundings 2
... world-renowned fragile X syndrome researcher, who was the first ... disorder, will be honored by the March of Dimes. ... Timmie Professor of Human Genetics and Charles Howard Candler ... as professor of biochemistry and pediatrics at Emory University ...
... of persons who smoked 20 or more cigarettes per day declined ... smoking 10 or more cigarettes a day, with these declines greater ... a study in the March 16 issue of JAMA . ... in the United States, consumption was typically 1 pack (about 20 ...
... by a new type of self-monitoring blood glucose sensor being ... Clinic in Arizona. More than 23 million people in ... leading cause of death in the United States. It contributes ... lower extremity amputations and other chronic conditions. Many people ...
... University doctor should be studied and copied as a way to ... problem of adding 40 million people to its health care system ... Health Team Model (FHT) could help ease the burden. "What we ... and efficient way of providing health care," says Walter Rosser, professor ...
... technique has demonstrated that it can measure the interactions between ... other biological molecules. These extremely difficult measurements can aid the ... percent of the 7,000 proteins in a human cell reside ... 60 to 70 percent of the signals that control the ...
... 15, 2011Since the first laparoscopic procedure was performed to ... University in St. Louis, this breakthrough minimally invasive technique ... This remarkable achievement is celebrated with a series of ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ...
Cached Medicine News:Health News:Fragile X researcher honored by March of Dimes 2Health News:Prevalence of heavy smokers in US decreases 2Health News:Prevalence of heavy smokers in US decreases 3Health News:New device holds promise of making blood glucose testing easier for patients with diabetes 2Health News:New device holds promise of making blood glucose testing easier for patients with diabetes 3Health News:New laser technique opens doors for drug discovery 2Health News:20th anniversary of first laparoscopic nephrectomy 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: